Viatris Wins Landmark First US Interchangeability Designation For Semglee
Allows Pharmacy Substitution For Insulin Glargine Biosimilar Rival To Lantus
Viatris has revealed its commercial strategy for its Semglee insulin glargine biosimilar in the US after winning a landmark first designation of interchangeability for the product from the FDA that will allow pharmacy-level substitution with a year of exclusivity.
